Orthocell’s (ASX: OCC) regenerative device, CelGro, is helping give mobility back to quadriplegic patients. 

Surgeons can use CelGro, a collagen-based device, to support the body’s own tissue regeneration capabilities by providing the ideal environment to guide the re-growth of nerve fibres.

“We’ve been able to use CelGro to improve the operative technique for repairing damaged nerves. As a result of that, we’re returning function to previously paralysed muscles in quadriplegic patients in what we believe is ground-breaking surgery. Seeing one of our patients progress from no strength in his arm and limited movement in his fingers and thumb to playing wheelchair rugby is extremely encouraging for our researchers and clinical partners, says CEO Paul Anderson.”

Clinical trials have also proven Orthocell’s other regenerative product, Ortho-ATI, the first injectable cell therapy in orthopaedics for tendon regeneration.

“Both products are in the clinical phase. We know how they perform, we know they’ve been de-risked. Our products have distinct advantages in non-surgical and surgical markets,” says Paul. 

Orthocell has approval in Europe with applications underway for approval in Australia and, most importantly, the US. Orthocell is preparing for entry into the US market by the middle of 2021.

Orthocell has patent protected IP, manufacturing facilities, and strong clinical connections in the target markets. This means Orthocell is well placed for international expansion.

“From an investment point of view, we’ve got an aggressive programme with important near term catalysts and fully funded for the next two and a half years” says Paul.

Today Orthocell’s CEO Paul Anderson joined us for our ‘Meet The CEO’ Live Investor Briefing. You can watch a recording of the session below, or you can click here to book into our next ‘Meet the CEOs ‘ session.

Recorded on 23rd September 2020 at 12pm (AEST).